Other languages Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.3992 ^USD	+4.86%		+17.41%	-48.82%

Jun. 27	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
Jun. 27	Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	Jun. 27
Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	Jun. 27
Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer	Jun. 01
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	Apr. 25
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	Mar. 14
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	Feb. 27
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	Feb. 01
Purple Biotech Ltd. Announces Executive Changes	Dec. 20
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21
Purple Biotech Closes $5 Million Registered Direct Offering	23-10-19
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action	23-10-06
Purple Biotech Reports Positive Interim Results From Study of NT219 Cancer Treatment Candidate	23-10-03
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	23-10-03
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22
Purple Biotech Reports Results of Dose Escalation Trial of CM24 in Advanced Pancreatic Cancer; Shares Fall	23-07-11
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients	23-07-11
Top Premarket Gainers	23-07-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Other languages

Filters